Cisplatin and etoposide in oesophageal cancer: a phase II study
1996

Cisplatin and Etoposide for Oesophageal Cancer

Sample size: 73 publication Evidence: moderate

Author Information

Author(s): TC Kok, A Van der Gaast, J Dees, WMH Eykenboom, H Van Overhagen, G Stoter, HW Tilanus, TAW Splinter

Primary Institution: University Hospital Rotterdam

Hypothesis

The study aims to determine the activity and toxicity of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus.

Conclusion

The combination of cisplatin and etoposide resulted in a 48% overall response rate in patients with advanced oesophageal cancer.

Supporting Evidence

  • The overall response rate was 48%, including five complete responses and 26 partial responses.
  • Median time to progression was 7 months.
  • Two patients experienced toxic deaths due to neutropenic sepsis.

Takeaway

Doctors tested two medicines, cisplatin and etoposide, to see if they could help people with a type of throat cancer, and many patients got better.

Methodology

A phase II trial was conducted with 73 patients receiving a combination of cisplatin and etoposide, with response and toxicity evaluated after treatment.

Potential Biases

Potential bias due to lack of a control group and the observational nature of the study.

Limitations

The study had a small sample size and included patients with varying degrees of disease progression.

Participant Demographics

Patients were mostly male, aged between 41 and 76, with a performance status of WHO 0-2.

Statistical Information

Confidence Interval

95% CI 35-60%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication